alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### Cornelius R. WOODS, Plaintiff-Appellant, v. Steven HILL; Ralph Wylie; Doyle Cox; Curtis E. Smith; Sherman Smith; Gary Pegram; Shaundra Patterson; Beverly McClain; Donald Petrisko; William Myles; Luther Hill; Robert Hill; Dennis Hawkins; Kevin Kiddy; Todd Hill; Does 1-20, inclusively; Joseph Brooks, Defendants—Appellees, v. United States of America, Movant—Appellee.

No. 05-6656.

United States Court of Appeals, Fourth Circuit.

Submitted Sept. 29, 2005.

Decided Oct. 6, 2005.

Cornelius R. Woods, Appellant Pro Se. Debra Jean Prillaman, Assistant United States Attorney, Richmond, Virginia, for Appellee.

Before WILKINSON, KING, and GREGORY, Circuit Judges.

Dismissed by unpublished PER CURIAM opinion.

Unpublished opinions are not binding precedent in this circuit. See Local Rule 86(c).

PER CURIAM:

Cornelius R. Woods seeks to appeal the magistrate judge’s order denying without prejudice Woods’ motion for appointment of counsel in this Bivens* action. This court may exercise jurisdiction only over final orders, 28 U.S.C. § 1291 (2000), and *236certain interlocutory and collateral orders, 28 U.S.C. § 1292 (2000); Fed.R.Civ.P. 54(b); *Cohen v. Beneficial Indus. Loan Corp.,*337 U.S. 541, 69 S.Ct. 1221, 93 L.Ed. 1528 (1949). The order Woods seeks to appeal is neither a final order nor an appealable interlocutory or collateral order. Accordingly, we dismiss the appeal for lack of jurisdiction. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

*DISMISSED*

*

*Bivens v. Six Unknown Named Agents of Fed. Bureau of Narcotics,*403 U.S. 388, 91 S.Ct. 1999, 29 L.Ed.2d 619 (1971).
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             DEC-27-1997
<PERIOD-END>                               SEP-26-1998
<CASH>                                           8,853
<SECURITIES>                                         0
<RECEIVABLES>                                   75,562
<ALLOWANCES>                                   (2,567)
<INVENTORY>                                     63,395
<CURRENT-ASSETS>                               176,215
<PP&E>                                         133,983
<DEPRECIATION>                                (69,502)
<TOTAL-ASSETS>                                 283,261
<CURRENT-LIABILITIES>                           63,395
<BONDS>                                         60,088
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           113
<OTHER-SE>                                     157,549
<TOTAL-LIABILITY-AND-EQUITY>                   157,662
<SALES>                                        199,998
<TOTAL-REVENUES>                               199,998
<CGS>                                          112,966
<TOTAL-COSTS>                                  112,966
<OTHER-EXPENSES>                                86,157
<LOSS-PROVISION>                                   194
<INTEREST-EXPENSE>                               3,469
<INCOME-PRETAX>                                    875
<INCOME-TAX>                                       344
<INCOME-CONTINUING>                                531
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       531
<EPS-PRIMARY>                                     0.06<F1>
<EPS-DILUTED>                                     0.06
<FN>
<F1>FOR PURPOSES OF THIS EXHIBIT, PRIMARY MEANS BASIC.
</FN>
        

</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                   605100
<ALLOWANCES>                                         0
<INVENTORY>                                    9115382
<CURRENT-ASSETS>                              14322748
<PP&E>                                        12328310
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                31117350
<CURRENT-LIABILITIES>                          9864264
<BONDS>                                        5681484
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        497795
<OTHER-SE>                                    15073807
<TOTAL-LIABILITY-AND-EQUITY>                  31117350
<SALES>                                       34865904
<TOTAL-REVENUES>                              34865904
<CGS>                                         21949005
<TOTAL-COSTS>                                 37498577
<OTHER-EXPENSES>                                266094
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              (2898767)
<INCOME-TAX>                                  (981915)
<INCOME-CONTINUING>                          (1916852)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (1916852)
<EPS-BASIC>                                   (0.39)
<EPS-DILUTED>                                   (0.39)


</TABLE>
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 957 Introduced in House (IH)]

<DOC>

115th CONGRESS
  2d Session
H. RES. 957

 Disapproving of the request of the President for the extension, under 
     section 103(c)(1)(B)(i) of the Bipartisan Congressional Trade 
  Priorities and Accountability Act of 2015, of the trade authorities 
   procedures under that Act to any implementing bill submitted with 
  respect to any trade agreement entered into under section 103(b) of 
                     that Act after June 30, 2018.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             June 22, 2018

Mr. Amash submitted the following resolution; which was referred to the 
Committee on Ways and Means, and in addition to the Committee on Rules, 
for a period to be subsequently determined by the Speaker, in each case 
for consideration of such provisions as fall within the jurisdiction of 
                        the committee concerned

_______________________________________________________________________

                               RESOLUTION

 
 Disapproving of the request of the President for the extension, under 
     section 103(c)(1)(B)(i) of the Bipartisan Congressional Trade 
  Priorities and Accountability Act of 2015, of the trade authorities 
   procedures under that Act to any implementing bill submitted with 
  respect to any trade agreement entered into under section 103(b) of 
                     that Act after June 30, 2018.

    Resolved, That the House of Representatives disapproves the request 
of the President for the extension, under section 103(c)(1)(B)(i) of 
the Bipartisan Congressional Trade Priorities and Accountability Act of 
2015, of the trade authorities procedures under that Act to any 
implementing bill submitted with respect to any trade agreement entered 
into under section 103(b) of that Act after June 30, 2018.
                                 <all>
```
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7373 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7373

 To direct the Secretary of Health and Human Services, acting through 
  the Director of the Centers for Disease Control and Prevention, to 
    include alpha-gal syndrome on the list of nationally notifiable 
                               diseases.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 15, 2024

      Mr. Garbarino (for himself, Ms. Spanberger, Mr. Thompson of 
Pennsylvania, and Ms. Norton) introduced the following bill; which was 
            referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
 To direct the Secretary of Health and Human Services, acting through 
  the Director of the Centers for Disease Control and Prevention, to 
    include alpha-gal syndrome on the list of nationally notifiable 
                               diseases.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Recognize AGS Act''.

SEC. 2. INCLUSION OF ALPHA-GAL SYNDROME ON LIST OF NATIONALLY 
              NOTIFIABLE DISEASES.

    The Secretary of Health and Human Services, acting through the 
Director of the Centers for Disease Control and Prevention, shall take 
such steps as may be necessary to include alpha-gal syndrome on the 
list of nationally notifiable diseases published by the Centers for 
Disease Control and Prevention.
                                 <all>
```
§ 501.5 Animal food; name and place of business of manufacturer, packer, or distributor. ( a ) The label of a food in packaged form shall specify conspicuously the name and place of business of the manufacturer, packer, or distributor.
( b ) The requirement for declaration of the name of the manufacturer, packer, or distributor shall be deemed to be satisfied, in the case of a corporation, only by the actual corporate name, which may be preceded or followed by the name of the particular division of the corporation. In the case of an individual, partnership, or association, the name under which the business is conducted shall be used.
( c ) Where the food is not manufactured by the person whose name appears on the label, the name shall be qualified by a phrase that reveals the connection such person has with such food; such as “Manufactured for ______,” “Distributed by ______,” or any other wording that expresses the facts.
( d ) The statement of the place of business shall include the street address, city, state, and ZIP Code; however, the street address may be omitted if it is shown in a current city directory or telephone directory. The requirement for inclusion of the ZIP Code shall apply only to consumer commodity labels developed or revised after the effective date of this section. In the case of nonconsumer packages, the ZIP Code shall appear either on the label or the labeling (including invoice).
( e ) If a person manufactures, packs, or distributes a food at a place other than his principal place of business, the label may state the principal place of business in lieu of the actual place where such food was manufactured or packed or is to be distributed, unless such statement would be misleading.
##### 



EXHIBIT 31.2
 CERTIFICATION PURSUANT TO
EXCHANGE ACT RULE 13a-14(a)
  1.
    
    I have reviewed this Report on Form 10-Q of International Absorbents Inc.;
 2.
    
    Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;
 3.
    
    Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;
 4.
    
    The registrants other certifying officer(s) and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) for the registrant and have:
 (a)
    
    Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is
made known to us by others within those entities, particularly during the period in
which this report is being prepared;
 (b)
    
    Evaluated the effectiveness of the registrants disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report
based on such evaluation; and
 (c)
    
    Disclosed in this report any change in the registrants internal control over
financial reporting that occurred during the registrants most recent fiscal quarter
(the registrants fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrants
internal control over financial reporting; and
 5.
    
    The registrants other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrants auditors and the
audit committee of the registrants board of directors (or persons performing the equivalent
functions):
 (a)
    
    All significant deficiencies and material weaknesses in the design or operation
of internal control over financial reporting which are reasonably likely to adversely
affect the registrants ability to record, process, summarize and report financial
information; and
 (b)
    
    Any fraud, whether or not material, that involves management or other employees
who have a significant role in the registrants internal control over financial
reporting.
 /s/  David H. ThompsonDavid H. ThompsonDate: September 15, 2005
    Secretary and Chief Financial Officer
§ 522.1850 Polysulfated glycosaminoglycan. ( a ) *Specifications.* ( 1 ) Each 1-milliliter (mL) ampule of solution contains 250 milligrams (mg) polysulfated glycosaminoglycan.
( 2 ) Each mL of solution packaged in 5-mL ampules or 20-, 30-, or 50-mL vials contains 100 mg polysulfated glycosaminoglycan.
( b ) *Sponsor.* See No. 010797 in § 510.600(c) of this chapter.
( c ) *Special considerations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( d ) *Conditions of use* — ( 1 ) *Horses* — ( i ) *Indications for use.* For the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
( ii ) *Amount* — ( A ) *Intra-articular use (carpal)* : 250 mg once a week for 5 weeks.
( B ) *Intramuscular use (carpal and hock)* : 500 mg every 4 days for 28 days.
( iii ) *Limitations.* Do not use in horses intended for human consumption.
( 2 ) *Dogs* — ( i ) *Indications for use.* For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.
( ii ) *Amount.* 2 mg per pound of body weight by intramuscular injection twice weekly for up to 4 weeks (maximum of 8 injections).
[72 FR 56896, Oct. 5, 2007, as amended at 74 FR 67816, Dec. 21, 2009]
§ 520.1242d Levamisole resinate. ( a ) *Specifications.* The drug is levamisole adsorbed on a resin, in a concentration equivalent to 10 percent levamisole hydrochloride. Each 2.05-ounce (58.1 gram) packet contains levamisole equivalent to 5.806 grams of levamisole hydrochloride.
( b ) *Sponsor.* See No. 043781 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.350 of this chapter.
( d ) *Conditions of use.* In swine it is used as follows: ( 1 ) *Amount.* The equivalent of 8 milligrams per kilogram of body weight, as a single dose, mixed in the animal's ration.
( 2 ) *Indications for use.* For the removal of and control of the following nematode infections: large roundworms (*Ascaris suum*), nodular worms (*Oesophagostomum* spp.), lungworms (*Metastrongylus* spp.), intestinal threadworms (*Strongyloides ransomi*), and swine kidney worms (*Stephanurus dentatum*).
( 3 ) *Limitations.* For pigs from weaning to market weight, mix one 58.1-gram packet of levamisole resinate containing the equivalent of 10-percent levamisole hydrochloride in 40 pounds of feed and administer 1 pound of medicated feed per 40 pounds of body weight as sole ration. For breeding swine, mix 1 packet of the 10-percent resinate in 16 pounds of feed and administer 1 pound of medicated feed per 100 pounds of body weight as sole ration. Administer as single doses. Withhold regular feed overnight and administer medicated feed the following morning. Do not withhold water during fasting. Do not treat within 72 hours of slaughter. Salivation or muzzle foam may be observed. The reaction will disappear a short time after feeding. If pigs are infected with mature lungworms, coughing and vomiting may be observed. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
[43 FR 18171, Apr. 28, 1978, as amended at 45 FR 3574, Jan. 18, 1980]
<PAGE>

                       CONSENT OF INDEPENDENT ACCOUNTANTS


We consent to the incorporation by reference in the Registration Statements
(Forms S-8 Nos. 333-4502, 33-98384 and 33-98386) pertaining to the 1995 Director
Stock Option Plan, 1993 Stock Option Plan and 1995 Employee Stock Purchase Plan
of PixTech, Inc. of our report dated February 24, 1997, with respect to the
consolidated financial statements of PixTech, Inc. included in the Annual Report
(Form 10-K) for the year ended December 31, 1996.


                                                               Ernst & Young LLP


New York, New York
March 24, 1997
ATTENTION 

Sheep Grazing in This Area

Livestock Protection Dogs in Use

Sheep operators use dogs to manage and protect their sheep by scaring off predators. The dogs are here to protect the sheep. If 

you do not appear to be a threat to the sheep, many times the dogs will just watch you.

FROM: TO:

USDA is an equal opportunity provider, employer, and lender. 

 Animal and Plant Health Inspection Service • Program Aid No. 2053 • Issued July 2010 • Slightly Revised July 2017

Please Avoid Conflict With Protection Dogs. Do:

4 Stop and dismount if mountain biking.

4 Put your bike between you and the dog.

4 Walk your bike until you are well past the sheep.

4 Keep your distance from the flock. 

4 Keep your dog(s) leashed at all times. 

4 Watch for the protection dog(s) and the herder.

4 Remain calm if a dog(s) approaches.

Don’t:

4 Hike or ride your all-terrain vehicle/mountain bike into or near the flock.

4 Make quick or aggressive movements around the dog(s) or sheep.

4 Attempt to hit or throw things at the dog(s) or sheep.

4 Yell at dog(s) or sheep, unless approached—then, yell “go back” or “no!”

4 Try to outrun the dog(s).

If you have questions about livestock protection dogs or other wildlife damage management issues, please call Wildlife 

Services—a program within the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service 

(APHIS)—at 1-866-4-USDA-WS (1-866-487-3297), or visit the APHIS Web site at www.aphis.usda.gov/wildlife-damage.
Exhibit 32.1



                  CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
                       PURSUANT TO 18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the  accompanying  Quarterly  Report on Form 10-Q of Momentum
Biofuels,  Inc. for the quarter ended June 30 2010, I, George Sharp,  Principal
Executive and Accounting  Officer of Momentum  Biofuels,  Inc., hereby certifies
pursuant to 18 U.S.C.  Section 1350,  as adopted  pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, to my knowledge, that:

a)   such  Quarterly  Report on Form 10-Q of  Momentum  Biofuels,  Inc.  for the
     quarter  ended June 30, 2010,  fully  complies  with the  requirements  of
     section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

b)   the information contained in such Quarterly Report on Form 10-Q of Momentum
     Biofuels,  Inc. for the quarter ended June 30, 2010,  fairly presents,  in
     all material respects, the financial condition and results of operations of
     Momentum Biofuels, Inc.


Date: August __, 2010


                             /s/George Sharp
                             ---------------
                             George Sharp, Chief Executive Officer
                             (Principal Executive and Accounting Officer)




This  certification  accompanies  the  Report  pursuant  to  Section  906 of the
Sarbanes-Oxley  Act of 2002 and shall not,  except to the extent required by the
Sarbanes-Oxley  Act of 2002,  be deemed  filed by the  Company  for  purposes of
Section 18 of the Securities Exchange Act of 1934, as amended.
Exhibit 31.1

 

 

# **CERTIFICATION**

# ** **

I, Terrence J. Scully,certify that:

 

1.  I have reviewed this annual report on Form10-K/A, and all reports on Form 8-K containing distribution or servicingreports filed in respect of periods included in the year covered by this annualreport, of Target Credit Card Master Trust;

 

# **2.  Based on my knowledge, the information inthese reports, taken as a whole, does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statementsmade, in light of the circumstances under which such statements were made, notmisleading as of the last day of the period covered by this annual report;**

# ** **

3.  Based on my knowledge, the distribution orservicing information required to be provided to the trustee by the servicerunder the pooling and servicing, or similar, agreement, for inclusion in thesereports is included in these reports;

 

4.  I am responsible for reviewing the activitiesperformed by the servicer under the pooling and servicing, or similar,agreement and based upon my knowledge and the annual compliance review requiredunder that agreement, and except as disclosed in the reports, the servicer hasfulfilled its obligations under that agreement; and

 

5.  The reports disclose all significantdeficiencies relating to the servicer’s compliance with the minimum servicingstandards based upon the report provided by an independent public accountant,after conducting a review in compliance with the Uniform Single AttestationProgram for Mortgage Bankers or similar procedure, as set forth in the poolingand servicing, or similar, agreement, that is included in these reports.

 

 
| Dated: May 6, 2005 |   | By                           | /s/ Terrence J. Scully |
|--------------------|--------|------------------------------|------------------------|
|               |   | Terrence J. Scully,          |
|               |   | Vice President and  Director |
_______________________________________ __ 

### Michigan Supreme Court 

# Order

Lansing, Michigan



## September 22, 2008 Clifford W. Taylor, Chief Justice



## 136621 Michael F. Cavanag h Elizabeth A. Weave r Marilyn Kell y Maura D. Corriga n Robert P. Young, Jr. 

## PEOPLE OF THE STATE OF MICHIGAN, Stephen J. Markman, 

## Plaintiff-Appellee, J ustices



## v SC: 136621 COA: 283433 Oakland CC: 2007-213521-FH TIMOTHY RONALD BROWN, Defendant-Appellant.

________________ _________________________/

On order of the Court, the application for leave to appe al the April 14, 2008 order of the Court of Appeals is considered and, pursuant to MCR 7.302(G)(1), in lieu of granting leave to appeal, we REMAND th is case to the Court of Appeals for consideration as on leave granted.

l0915 I, Corbin R. Davis, Clerk of the Mi chigan Supreme Cour t, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

September 22, 2008

Clerk